You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

News

Getinge makes additional provisions of MSEK 350 in relation to Brazilian investigations

Gothenburg, Sweden March 21, 2018

Getinge makes additional provisions of MSEK 350 in relation to Brazilian investigations

Getinge has today decided to make an additional provison of MSEK 350 related to, among other things, alleged fraud in bidding proceedings in Brazil mainly attributable to the years 2004-2015, primarily involving Getinge’s Brazilian subsidiaries Maquet Cardiopulmonary do Brasil Indústria e Comércio Ltda and Maquet do Brasil Equipamentos Médicos Ltda. The additional provision will have effect on the operating profit of the first quarter 2018.

In connection with the Year-End Report 2017, Getinge made initial provisions of MSEK 69 for costs related to the Brazilian investigations, which means that in total, MSEK 419 has been allocated to the ongoing investigations.

Negotiations will continue with relevant authorities and are expected to be finalized during 2018. It cannot be excluded that settlements with relevant authorities will have additional significant effect on the result and financial position of Getinge.


Contact

Jeanette Hedén Carlsson
Executive Vice President Communications & Brand Management
Phone: +46 (10) 335 10 03
Email: jeanette.hedencarlsson@getinge.com

Lars Mattsson
Head of Investor Relations
Phone: +46 (0)10 335 00 43
Email: lars.mattsson@getinge.com

This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.30 CET on March 21, 2018.


About Getinge

Getinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our firsthand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people - today and tomorrow.

Files

Share: